Clinical utility of anti-p53 auto-antibody: Systematic review and focus on colorectal cancer

Table 6 Anti-p53 auto-antibody and prognosis in colorectal cancer

Ref.	n (%)	Follow-up	Findings
Suppiah et al[130]	20/92 (21.7)	Median 97 mo	No difference in overall survival (62 mo vs 60 mo) or disease-free survival (73 mo vs 82 mo)
Müller et al[123]	70/243 (28.8)	5-year trial protocol	No survival difference with anti-p53 in CRC and other cancers. Trend towards decreased survival in anti-p53 positive patients with HCC and breast carcinoma
Tang et al[89]	130/998 (13)	Recruitment 1995-2000	Anti-p53 associated with decreased survival in univariate analysis but not multivariate analysis. Anti-p53 associated with advanced nodal disease (Stage N2→N3) and metastases (M1)
Chang et al[85]	147/167 (28)	Median 36.3 mo (22-85)	p53 mutation associated with poor differentiation and advanced stage. Multivariate analysis shows p53 mutation most significant survival predictor, followed by CRC stage. No prognostic significance of p53 protein expression or anti-p53
Shiota et al[112]	18/71 (25)	Not stated	Anti-p53 associated with shorter overall survival (20 mo vs 56 mo) but highly significant association with metastases (M1). Cox regression showed prognostic significance with liver metastases, TNM stage, Dukes stage, Ca19-9 and anti-p53 (in that order)
Kressner et al[131]	59/184 (32.1)	Median 6 years	Anti-p53 associated with decreased survival in univariate, but not multivariate analysis. Anti-p53 is independent prognostic indicator in Dukes’ A-C with curative surgery (i.e., when metastases excluded)
Houbiers et al[132]	65/255 (25.5)	36 mo	Anti-p53 associated with reduced overall (75% vs 88%) and disease-free survival (56% vs 64%) at 3 years in subgroup analysis of Dukes’ A and B1. No difference in overall survival (61% vs 68%) or disease-free survival (51% vs 58%) when all stages included

CRC: Colorectal cancer; HCC: Hepatocellular carcinoma.